MET and non-small cell lung carcinoma: We also demonstrate that inhibition of MEK, EGFR, MET, or PDGFRA is unable prevent activation of STAT3 in NSCLC, suggesting that these hyperactive growth factor signaling pathways do not play a major role in the constitutive activation of STAT3.